Qian, Wendi
Cambridge University Hospitals NHS Foundation Trust · Cambridge Clinical Trials Unit
2 papers on CoChatORCID 0000-0002-4238-3471
Most cited papers
- Verified
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Abraham, J. E., Pinilla, K., Dayimu, A., Grybowicz, L., Demiris, N., Harvey, C., Drewett, L. M., Lucey, R., Fulton, A., Roberts, A. N., et al. (2024) · Nature
PARP inhibition in cancer therapyBreast Cancer Treatment Studies
Cited by 53
- Verified
PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and/or germline BRCA-mutated breast cancer.
Drewett, L., Lucey, R., Pinilla, K. A., Grybowicz, L., Wulff, J., Dayimu, A., Demiris, N., Vallier, A.-L., Qian, W., Machin, A., et al. (2022) · Journal of Clinical Oncology
PARP inhibition in cancer therapyBRCA gene mutations in cancer
Cited by 6
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free